The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian
flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down
into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test
article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment
following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts
of the study.